高危雌激素受体阳性HER2阴性乳腺癌患者接受新辅助来曲唑联合哌柏西利对比第三代化疗后的生存结局
NEOPAL是一项多中心国际随机2期试验,比较来曲唑-哌柏西利联合方案与序贯蒽环-紫杉类化疗在高危ER阳性/HER2阴性绝经后乳腺癌中的疗效。中位随访40.4个月,两组无进展生存期(PFS)和无侵袭性疾病生存期(iDFS)无显著差异,未接受化疗患者结局与接受化疗者无统计学差异。作者认为该策略或可在部分luminal乳腺癌患者中免除化疗,但需更大样本验证。
要点
- 来曲唑-哌柏西利组与化疗组PFS的HR=1.01(95%CI 0.36-2.90,p=0.98),无显著差异。
- 两组iDFS的HR=0.83(95%CI 0.31-2.23,p=0.71),无显著差异。
- 未接受化疗患者结局与接受化疗者无统计学差异,作者认为或可免除化疗但需更大样本验证。
核心结论
- NEOPAL提示新辅助来曲唑-哌柏西利策略或可在部分luminal乳腺癌患者中免除化疗,同时获得良好长期结局,但需更大规模验证性研究。
研究设计与样本
- 次要终点为意向治疗人群的PFS和iDFS;探索性终点为意向治疗人群的OS和BCSS,以及按是否接受化疗分层的iDFS、OS和BCSS。
主要发现
- 病理完全缓解率分别为3.8%和5.9%。
- 来曲唑-哌柏西利组53例患者中23例接受术后辅助化疗。
- 中位随访40.4个月[0-56.6]期间共观察到11例进展,其中来曲唑-哌柏西利组3例、对照组8例。
- PFS的HR=1.01(95%CI 0.36-2.90,p=0.98),iDFS的HR=0.83(95%CI 0.31-2.23,p=0.71),两组间无显著差异。
- 40个月PFS率来曲唑-哌柏西利组为86.7%[95%CI 78.0-96.4],对照组为89.9%[95%CI 81.8-98.7]。
局限性
- 原文结论指出需更大规模验证性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Besides their development as additional adjuvant treatments, CDK4/6 inhibitors combined with endocrine therapy could represent less toxic alternatives to chemotherapy in postmenopausal women with high-risk oestrogen receptor-positive, HER2-negative breast cancer currently a candidate for chemotherapy. The multicentre, international, randomised phase 2 NEOPAL trial showed that the letrozole-palbociclib combination led to clinical and pathological responses equivalent to sequential anthracycline-taxanes chemotherapy. Secondary objectives included survival outcomes. METHODS: Secondary end-points of NEOPAL included progression-free survival (PFS) and invasive-disease free survival (iDFS) in the intent-to-treat population. Exploratory end-points were overall survival (OS) and breast cancer specific survival (BCSS) in the intent-to-treat population, as well as iDFS, OS and BCSS according to the administration of chemotherapy. RESULTS: Hundred and six patients were randomised. Pathological complete response rates were 3.8% and 5.9%. Twenty-three of the 53 patients in the letrozole-palbociclib arm received postoperative adjuvant chemotherapy. At a median follow-up of 40.4 months [0-56.6], 11 progressions have been observed, of which three were in the letrozole-palbociclib and 8 in the control arm. PFS (HR = 1.01; [95%CI 0.36-2.90], p = 0.98) and iDFS (HR = 0.83; [95%CI 0.31-2.23], p = 0.71) did not differ between both arms. The 40 months PFS rate was 86.7% [95%CI 78.0-96.4] and 89.9% [95%CI 81.8-98.7] in letrozole-palbociclib and control arms, respectively. Outcomes of patients who did not receive chemotherapy were not statistically different from those who received it. CONCLUSIONS: NEOPAL suggests that a neoadjuvant letrozole-palbociclib strategy may allow sparing chemotherapy in some patients with luminal breast cancer while allowing good long-term outcomes. Larger confirmatory studies are needed.
引用
- Delaloge S, Dureau S, D'Hondt V, et al. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. Eur J Cancer. 2022. PMID: 35337692. doi:10.1016/j.ejca.2022.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。